enGene Holdings Inc
Research enGene Holdings Inc (ENGN) on Bullrun: market cap USD 115.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerENGN
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 115.93M
- Financial periodQ3 2026
- RevenueUSD 0
- Net income-USD 32.50M
- Free cash flow-USD 18.95M
Valuation Snapshot
latest market cap is USD 115.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 117.30M | -USD 100.72M | n/a | 2.29 | USD 50.15M | USD 31.80M | USD 167.71M |
| FY2024 | USD 0 | -USD 55.14M | -USD 49.21M | n/a | 1.46 | USD 173.00M | USD 25.02M | USD 272.61M |
| FY2023 | USD 0 | -USD 99.92M | -USD 25.06M | n/a | 151.22 | USD 81.52M | USD 9.78M | USD 72.49M |
| FY2022 | USD 0 | -USD 24.46M | -USD 17.75M | n/a | 44.3 | USD 20.43M | USD 32.11M | -USD 76.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 115.93M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 604.87M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 339.00M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 214.12M | n/a | n/a | n/a |
About enGene Holdings Inc
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is enGene Holdings Inc's market cap?
enGene Holdings Inc's market capitalization is USD 115.93M.
What does enGene Holdings Inc do?
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.